The Record header image

Subscribe  |  The Record Archive  |  Contacts  |  bcbsm.com

May 2023

All Providers

Do you know about our BlueCard processes?

At Blue Cross Blue Shield of Michigan, we want to ensure that health care providers have the information they need about BlueCard®. This national program enables members of one Blue Cross Blue Shield plan to obtain health care services while traveling or living in another Blue Cross Blue Shield plan's service area.

About BlueCard

The program links participating health care providers with independent Blue Cross Blue Shield plans across the United States and in more than 200 countries and territories worldwide through a single electronic network for claims processing and reimbursement. The BlueCard program lets you conveniently submit claims for members from other Blue Cross Blue Shield plans, including international Blue Cross Blue Shield plans, directly to Blue Cross Blue Shield of Michigan. Blue Cross is your single point of contact for all your claims-related questions.

Verifying coverage and eligibility

When a member from an out-of-state Blue Cross Blue Shield plan (the home plan) requests care and presents a current Blue Cross Blue Shield identification card, prior to providing services, you (as the service provider for the host plan), should:

  • Make copies of the front and back of the subscriber's ID card
  • Verify membership and eligibility with the member’s home plan by one of the following methods:
    • Calling BlueCard Eligibility Call Center
    • Accessing eligibility and benefits on Availity®, our provider portal

Members with coverage from a Blue Cross Blue Shield plan may also present a debit card, which may be Blue-branded, to cover cost-sharing payments.

BlueCard Eligibility Call Center

Call the BlueCard Eligibility Call Center at 1-800-676-2583. State the three-character alpha-numeric prefix on the patient's ID card, and you’ll be connected with the patient's home plan to verify eligibility and benefits for health care coverage.

Prior authorization

You can call the BlueCard Eligibility Call Center and choose the appropriate prior authorization prompt, or you can use the Authorizations & Referrals page on Availity®, our provider portal.

Timely filing

All original facility claims must be reported to Blue Cross within 12 months from the date of service and all original professional claims must be reported to Blue Cross within 180 days of the date of service. All claim adjustment requests for both professional and facility claims must be billed to Blue Cross within 24 months of the date of service.

For more details, including information on how to submit claims for various services, see the “BlueCard Program” chapter of the Blue Cross Commercial Provider Manual.

Availity is an independent company that contracts with Blue Cross Blue Shield of Michigan and Blue Care Network to offer provider portal services.


Here’s more information about changes that will result from end of COVID-19 public health emergency

On Jan. 30, 2023, the White House announced that it will end the public health emergency on May 11, 2023.

As we’ve reported previously, Blue Cross Blue Shield of Michigan and Blue Care Network enacted temporary measures to support providers and protect members during the COVID-19 pandemic. Now that the public health emergency is ending, you need to know which temporary measures are continuing and which are ending.

Check out our Temporary changes due to the COVID-19 pandemic document. We’ve been regularly updating this as we determine which temporary changes become permanent and which will end.

Several temporary measures to continue

Here are a few examples of changes that are no longer temporary and will continue after the public health emergency ends:

  • For all members in group or individual plans covered by the Patient Protection and Affordable Care Act, cost sharing will continue to be waived for both the COVID-19 vaccine product and its administration when the vaccine is provided in network.
  • For all members, specific COVID-19 and influenza testing will continue to be payable in a physician office setting.
  • For all members, durable medical equipment, prosthetics, orthotics and medical supplies can continue to be prescribed through telemedicine visits.

Coverage for certain other temporary measures to end

Here are a couple examples of temporary changes that are ending when the public health emergency ends:

  • Expanded laboratory networks — Our lab network was temporarily expanded for COVID-19 testing during the pandemic. We return to our standard lab networks beginning May 12. Direct any patients who need a COVID-19 test to an in-network lab. As a reminder, Medicare Plus Blue℠ uses JVHL, LabCorp or Quest Diagnostics labs. Blue Care Network and BCN Advantage℠ use JVHL labs.
  • Over-the-counter COVID-19 tests – During the pandemic, we covered over-the-counter at-home rapid diagnostic COVID-19 tests for members with Blue Cross or BCN pharmacy coverage. This coverage ends with the ending of the public health emergency on May 11.

For other temporary measures that have ended, see the Temporary changes due to the COVID-19 pandemic document.

Resources

Here are some additional resources for information related to the end of the public health emergency.

Through May 11, we’ll continue to update the Temporary changes due to the COVID-19 pandemic document as decisions are made.

As a reminder, you can view our COVID-19 provider communications as follows:

  • Log in to our provider portal (availity.com).**
  • Click on Payer Spaces in the menu bar and then click on the BCBSM and BCN logo.
  • Click on the Resources tab.
  • Click on Secure Provider Resources (Blue Cross and BCN).
  • Under Easy Access, click on Coronavirus information.

You can also access these communications on the COVID-19 webpage for health care providers on our public website.

**Blue Cross Blue Shield of Michigan and Blue Care Network don’t own or control this website.

Availity is an independent company that contracts with Blue Cross Blue Shield of Michigan and Blue Care Network to offer provider portal and electronic data interchange services.


Blue Cross expanding covered services for substance use disorders and mental health

Effective July 1, 2023, we’ll cover the following as standard benefits for all Blue Cross Blue Shield of Michigan commercial members:

  • Partial hospitalization program services for substance use disorders
  • Intensive outpatient program services for mental health

Currently, Blue Cross covers partial hospitalization program services only for mental health and intensive outpatient program services only for substance use disorders.

Blue Care Network already covers these services, as do some groups with Blue Cross commercial coverage.

Aligning these benefits across our Blue Cross and BCN lines of business will do the following for our Blue Cross commercial members:

  • Help reduce inpatient stays.
  • Provide additional step-down options.
  • Increase access to care.

 This change won’t affect members’ out-of-pocket costs.

Additional information

Partial hospitalization program services will continue to require prior authorization through New Directions.  For more information, see the For Blue Cross commercial members section of the Blue Cross Behavioral Health page on our ereferrals.bcbsm.com website. 


Prior authorization processes for MESSA members to change June 1

Michigan’s prior authorization law requirements** go into effect on June 1, 2023. These requirements apply to health plans and health care providers in Michigan for members who have commercial coverage. One of the requirements is that health plans must provide an online method through which providers can submit prior authorization requests for all services.

The Michigan Education Special Services Association, known as MESSA, manages most prior authorization requests for its members, with exceptions for certain services. Online submission tools for submitting prior authorization requests for MESSA members are shown in the table below — including a new online method for submitting requests to MESSA.

Note: Alternate submission methods will continue to be available for situations when providers are unable to submit requests online. Those occasions include power and internet outages, and similar events.

Managed by

Service

To submit requests

More information

MESSA — new online method

Services that require prior authorization and are processed by MESSA include:

  • Behavioral health admissions submitted by health care providers who aren’t contracted with Blue Cross Blue Shield of Michigan (nonparticipating)
  • Inpatient medical and surgical admissions to facilities outside of Michigan
  • Inpatient rehabilitation admissions
  • Long-term acute care hospital admissions
  • Private duty nursing

Online: Use the MESSA provider portal.** (Acuity Connect™ collaboration portal). The portal will be available, starting June 1, 2023.

Alternate methods

For hospital admissions:

  • Fax: 517-203-2998
  • Call: 1-800-336-0022

For private duty nursing: Call: 1-800-441-4626

For all other services: Call: 1-800-336-0013

Visit the Prior authorization page on the MESSA website.** This webpage will be available before June 1.

Blue Cross

Medical benefit drugs: non-oncology

Online: Use the NovoLogix® online tool, accessed through availity.com.**

Alternate methods

  • Fax: 1-866-601-4425
  • Call: 1-800-437-3803

Visit the Blue Cross Medical Benefit Drugs page on ereferrals.bcbsm.com.

Pharmacy benefit drugs

Online: Submit through an electronic prior authorization, or ePA, tool.

Alternate methods

  • Fax: 1-866-601-4425
  • Call: 1-800-437-3803

Visit the Blue Cross Pharmacy Benefit Drugs page on ereferrals.bcbsm.com.

Alacura Medical Transport

Non-emergency air ambulance flights

Online: An electronic prior authorization process will be in place by June 1. We’ll provide more information through a future provider alert or Record article.

Alternate method
Fax the Air ambulance flight information (non-emergency) form to the fax number on the form.

 

Carelon Medical Benefits Management (formerly AIM Specialty Health®)

  • Cardiac imaging
  • High-technology radiology
  • In-lab sleep studies

Online: Carelon ProviderPortal**

Alternate method
Call: 1-800-728-8008

Visit the Blue Cross Carelon-Managed Procedures page on ereferrals.bcbsm.com.

Medical benefit drugs: medical oncology and supportive care

Visit the Blue Cross Medical Benefit Drugs page on ereferrals.bcbsm.com.

New Directions® Behavioral Health

Behavioral health admissions submitted by health care providers who are contracted with Blue Cross (participating)

Online: Use the New Directions WebPass tool, accessed through availity.com**

Alternate method
Call: 1-800-762-2382

Visit the Blue Cross Behavioral Health webpage on ereferrals.bcbsm.com.


**Blue Cross Blue Shield of Michigan and Blue Care Network don’t own or control this website.

Alacura Medical Transport Management is an independent company that manages the authorization of non-emergency flights for Blue Cross Blue Shield of Michigan and Blue Care Network members who have commercial plans.

Availity® is an independent company that contracts with Blue Cross Blue Shield of Michigan and Blue Care Network to offer provider portal services.

Carelon Medical Benefits Management is an independent company that contracts with Blue Cross Blue Shield of Michigan and Blue Care Network to manage authorizations for select services. For more information, go to our ereferrals.bcbsm.com website.

New Directions Behavioral Health is an independent company that manages authorizations for behavioral health and autism services for Blue Cross Blue Shield of Michigan members who have commercial plans.


EDI transitioning to Availity starting in 2023

Blue Cross Blue Shield of Michigan and Blue Care Network will move our electronic data interchange services, known as EDI, to Availity® beginning in August 2023.

The EDI transition affects HIPAA electronic transactions. The transition will occur in phases, starting with claims (837) and remittance (835) transactions, but all electronic transactions will transition to Availity. Examples of electronic transactions include the electronic 837 claims, 835 electronic remittance advice, 270/271 eligibility and benefit, 276/277 claim status and 278 prior authorizations.

This transition includes electronic transactions for all Blue Cross and BCN fully insured and self-funded health plans. This includes:

  • Blue Cross commercial, including the Federal Employee Program®
  • Medicare Plus Blue℠, our Medicare Advantage PPO plan
  • Blue Care Network commercial
  • BCN Advantage℠, our Medicare Advantage HMO and POS plans
  • Blue Cross® Complete

If you submit HIPAA EDI transactions to Blue Cross for payers other than Blue Cross and BCN and our health plans listed above, you’ll need to find a new method to submit those transactions. Blue Cross Blue Shield of Michigan EDI will no longer accept non-Blue Cross and BCN health plan transactions once our EDI transitions to Availity.

Many of our EDI submitters and trading partners already submit to Availity’s EDI clearinghouse for other health plans. In 2022, Blue Cross and BCN moved our provider portal to Availity’s secure platform where you can find information for members associated with multiple health plans.

We expect the EDI transition to begin in August 2023.

Availity will handle all transition activities and will start sending communications to our EDI submitters and trading partners 90 to 120 days prior to the transition.

  • If you use a submitter or trading partner to exchange electronic transactions with us, check with them to ensure they’re working with Availity on this transition.
  • If you currently submit HIPAA EDI transactions today directly to Blue Cross and believe we may not have your most up-to-date email on file, reach out to partnermanagement@availity.com to update your contact information.

If you have any questions about the EDI transition, send an email to partnermanagement@availity.com. Don’t contact Blue Cross EDI.

Availity is an independent company that contracts with Blue Cross Blue Shield of Michigan and Blue Care Network to offer provider portal and electronic data interchange services.


Reminder: Reporting instructions for Blue Cross or FEP supplemental when Medicare Advantage is primary payer

When a member has a Medicare Advantage or Medicare Advantage HMO primary and a Blue Cross Blue Shield of Michigan or Blue Cross and Blue Shield Federal Employee Program® supplemental policy, remember to report the primary payer with a claim filing indicator of MA or MB in loop 2320.

Institutional:

  • Loop 2000B SBR09: Report claim filing indicator BL or FI
  • Loop 2320 SBR09: Report claim filing indicator MA when the primary payer is Original Medicare, any type of Medicare Advantage or Medicare Advantage HMO

Professional:

  • Loop 2000B SBR09: Report claim filing indicator BL or FI.
  • Loop 2320 SBR09: Report claim filing indicator MB when the primary payer is Original Medicare, any type of Medicare Advantage or Medicare Advantage HMO.

Has the member responded to the Letter of Other Insurance inquiry? Members can update their coverage details with Blue Cross by the following methods:

  • Phone — Call our automated response line at 1-866-263-9494 or the Customer Service line on the back of their member ID card.
  • BCBSM mobile app — Log in, click on the menu button in the top left corner, then click on My Account, followed by Coordination of Benefits and follow the instructions.
  • Online — Visit bcbsm.com/cob and select a radio button (either “Yes, I have coverage from another health insurance company” or “No, I don't have additional coverage”). Then click on the Login and Update button and follow the instructions.

Allow up to five business days for Blue Cross to process the requested changes.


Billing chart: Blue Cross highlights medical, benefit policy changes

You’ll find the latest information about procedure codes and Blue Cross Blue Shield of Michigan billing guidelines in the following chart.

This billing chart is organized numerically by procedure code. Newly approved procedures will appear under the New Payable Procedures heading. Procedures for which we have changed a billing guideline or added a new payable group will appear under Updates to Payable Procedures. Procedures for which we are clarifying our guidelines will appear under Policy Clarifications. New procedures that are not covered will appear under Experimental Procedures.

We'll publish information about new Blue Cross groups or changes to group benefits under the Group Benefit Changes heading.

For more detailed descriptions of the Blue Cross' policies for these procedures, check under the Commercial Policy tab in Benefit Explainer on Availity®. To access this online information:

    1. Log in to availity.com.
    2 .Click on Payer Spaces on the Availity menu bar.
    3. Click on the BCBSM and BCN logo.
    4. Click on Benefit Explainer on the Applications tab.
    5. Click on the Commercial Policy tab.
    6. Click on Topic.
    7. Under Topic Criteria, click on the circle for Unique Identifier and click the drop-down arrow next to Choose Identifier Type, then click on HCPCS Code.
    8. Enter the procedure code.
    9. Click on Finish.
    10. Click on Search.
Code* BCBSM changes to:
Basic Benefit and Medical Policy, Group
Variations Payment Policy, Guidelines
NEW PAYABLE PROCEDURES

90626, 90627

Basic benefit and medical policy

Ticovac

Ticovac™ is a vaccine indicated for active immunization to prevent tick-borne encephalitis. Ticovac is FDA approved for use in individuals ages 1 year and older. This policy is effective Aug. 13, 2021 (FDA approval).       

Basic benefit policy group variations:

Note: Coverage is based on the member’s certificate benefits and may not be covered on all contracts. Reference member benefits before administering procedure.

POLICY CLARIFICATIONS

78608, 78609, 78811, 78812, 78813,  78814, 78815, 78816, 78999, G0235, A9593, A9594, A9595, A9800

Not covered:

G0219, G0252

Basic benefit and medical policy

PET for oncologic conditions

The safety and effectiveness of PET scanning for select oncologic applications have been established. It’s a useful diagnostic option for individuals meeting patient selection criteria.

Inclusionary criteria for the following conditions have been updated, effective March 1, 2023:      

  • Anal cancer
  • Bladder cancer
  • Bone cancer/sarcoma
  • Brain cancer
  • Colorectal cancer
  • Head and neck cancer
  • Penile cancer
  • Soft tissue sarcoma
  • Testicular cancer
  • Vaginal/vulvar cancers

Inclusions:

All inclusionary and exclusionary statements apply to both positron emission tomography, or PET, scans and PET/CT scans, i.e., PET scans with or without PET/CT fusion.

A PET or PET/CT may be appropriate for a patient with known diagnosis of a malignancy in order to determine the optimal anatomic site for a biopsy or other invasive diagnostic procedure if standard imaging is equivocal. It also may replace conventional imaging when conventional imaging would be inadequate for accurate staging, and when clinical management will depend upon the stage of disease. In general, for most solid tumors, a tissue diagnosis is made before the performance of PET scanning. PET scans following a tissue diagnosis are performed for staging, not diagnosis. If the results of the PET scan won’t influence treatment decisions, these situations would be considered not medically necessary.

PET scans may be considered appropriate for the following oncologic conditions:

Anal cancer

Inclusions:

  • For the diagnosis when standard imaging can’t be performed or is nondiagnostic for metastatic disease.
  • Indicated in either of the following:
    • Radiation planning for definitive treatment only
    • Standard imaging can’t be performed or is nondiagnostic for recurrent or progressive disease
  • For locally progressive or recurrent cancer with evidence of progression found on digital rectal exam.

Exclusions:

  • Conditions not listed above

Bladder cancer

Inclusions:

  • Diagnostic workup:
    • Evaluation of stage II or stage III bladder cancer prior to definitive treatment when standard imaging can’t be performed or is nondiagnostic for metastatic disease
    • When bone metastasis is suspected based on signs and symptoms and standard imaging can’t be performed or is nondiagnostic
  • Management:
    • Standard imaging can’t be performed or is nondiagnostic for recurrent or progressive disease.

Exclusions:

  • Conditions not listed above

Bone cancer/sarcoma

Inclusions:

  • Diagnostic workup (indicated in any of the following scenarios [all tumor types]):
    • Initial workup of Ewing sarcoma and osteosarcoma if curative treatment planned
    • Standard imaging can’t be performed or is nondiagnostic for metastatic disease
    • Standard imaging suggests a resectable solitary metastasis
    • Baseline study prior to neoadjuvant chemotherapy
  • Management:
    • Indicated following completion of neoadjuvant chemotherapy

Exclusions:

  • Conditions not listed above

Brain cancer
 
Inclusions:

  • Diagnostic workup:
    • Evaluation of possible systemic disease in proven CNS lymphoma
  • For staging, where lesions metastatic from the brain are identified
  • For restaging, to distinguish recurrent tumor from radiation necrosis

Exclusions:

  • Conditions not listed above

Colorectal cancer

Inclusions:

  • Diagnostic workup:
    • Indicated when standing imaging (CT chest, abdomen and pelvis) can’t be performed or isn’t diagnostic for surgically curable metastatic disease
  • Management:
    • Indicated in any of the following scenarios:
      • CT is equivocal for metastatic disease and lesion are greater than 1 cm in diameter.
      • CT demonstrates recurrence that is potentially curable with surgery.
      • CT doesn’t demonstrate a focus of recurrence but carcinoembryonic antigen, or CEA, level is rising.
      • Signs or symptoms are suggestive of recurrence and CT is contraindicated.

Exclusions:

  • When used as a technique to assess the presence of scarring versus local bowel recurrence in individuals with previously resected colorectal cancer
  • When used as a technique contributing to radiotherapy treatment planning

Head and neck cancer

Inclusions:

  • For the evaluation of the head and neck in the initial diagnosis of suspected head and neck cancer
  • For the initial staging of the disease
  • For restaging of residual or recurrent disease during follow up
  • Evaluation of response to treatment

Exclusions:

  • Conditions not listed above

Penile cancer

Inclusions:

  • Diagnostic workup:
    • Indicated in either of the following scenarios:
      • Standard imaging can’t be performed or is nondiagnostic for metastatic disease.
      • Staging of penile cancer when pelvic lymph nodes are enlarged on CT or MRI and needle biopsy isn’t technically feasible
  • Management:
    • Indicated in any of the following scenarios:
      • Radiation planning for preoperative or definitive treatment only
      • Standard imaging can’t be performed or is nondiagnostic for recurrent or progressive disease
      • Restaging of local recurrence when pelvic exenteration surgery is planned

  Exclusions:

  • All other indications

Soft tissue sarcoma

Inclusions:

  • Diagnostic workup:
    • Indicated in any of the following scenarios (excluding desmoid tumors):
      • Standard imaging can’t be performed or is nondiagnostic for metastatic disease
      • Standard imaging suggests a resectable solitary metastasis
      • Baseline study prior to neoadjuvant chemotherapy
      • Initial staging for rhabdomyosarcoma
      • Determination of response to therapy, gastrointestinal stromal tumor for initial staging and re-staging when there is documented recurrence
  • Management:
    • Indicated following completion of neoadjuvant chemotherapy

Exclusions:

  • When used in evaluation of soft tissue sarcoma including, but not limited to, the following applications:
    • Distinguishing between low grade and high-grade soft tissue sarcoma
    • Detecting locoregional recurrence
    • Detecting distant metastasis

Testicular cancer

Inclusions:

  • Diagnostic workup:
    • Indicated when standard imaging can’t be performed or is nondiagnostic for metastatic disease
  • Management:
    • Standard imaging can’t be performed or is nondiagnostic for recurrent or progressive disease
    • Residual mass greater than 3 cm and normal tumor markers after completion of chemotherapy

Exclusions:

  • All other indications

Vaginal/vulvar cancers

Inclusions:

  • Diagnostic workup:
    • Indicated in either of the following scenarios:
      • Standard imaging can’t be performed or is nondiagnostic for metastatic disease
      • Staging of penile cancer when pelvic lymph nodes are enlarged on CT or MRI and needle biopsy isn’t technically feasible
  • Management:
    • Indicated in any of the following scenarios:
      • Radiation planning for preoperative or definitive treatment only
      • Standard imaging can’t be performed or is nondiagnostic for recurrent or progressive disease
      • Restaging of local recurrence when pelvic exenteration surgery is planned

Exclusions:

  • All other indications

Note: This notification doesn’t include all the conditions addressed in the medical policy because of the lengthy list. Reference the policy itself if a condition isn’t addressed here.

89344

Basic benefit and medical policy

*89344 on Physician Office Laboratory List

Procedure code *89344 has been added to the Physician Office Laboratory List. It can be performed in a physician’s office.

90715

Basic benefit and medical policy

Boostrix (tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed)

Effective Oct. 10, 2022, Boostrix (tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed) is covered for the following FDA-approved indications:

Boostrix (tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed) is a vaccine indicated for the following:

  • Active booster immunization against tetanus, diphtheria and pertussis in individuals ages 10 and older
  • Immunization during the third trimester of pregnancy to prevent pertussis in infants younger than 2 months of age

Dosage and administration:

For intramuscular use only.

  • Each dose of Boostrix (tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed) is administered as a 0.5-mL injection.
  • An initial dose of Boostrix (tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed) is administered five years or more after the last dose of the diphtheria and tetanus toxoids and acellular pertussis, or DTaP, series or five years or more after a dose of tetanus and diphtheria toxoids adsorbed, or Td. Boostrix (tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed) may be administered as an additional dose nine years or more after the initial dose of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed, or Tdap.
  • Boostrix (tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed) may be administered for tetanus prophylaxis for wound management. For management of a tetanus-prone wound, a dose of Boostrix (tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed) may be administered if at least five years have elapsed since previous receipt of a tetanus toxoid-containing vaccine.
  • To provide protection against pertussis in infants younger than 2 months of age, administer Boostrix (tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed) during the third trimester of pregnancy.

J0179

    

Basic benefit and medical policy

Beovu (brolucizumab-dbll)

The FDA has updated the payable indications for Beovu (brolucizumab-dbll), effective May 27, 2022. The payable indications include diabetic macular edema.

J0224

Basic benefit and medical policy

Oxlumo (lumasiran)

Effective Oct. 6, 2022, Oxlumo (lumasiran) is covered for the following FDA-approved indications:

  • Oxlumo is a HAO1-directed small interfering ribonucleic acid, or siRNA, indicated for the treatment of primary hyperoxaluria type 1 to lower urinary and plasma oxalate levels in pediatric and adult patients.

Dosage and administration:

The recommended dose of Oxlumo by subcutaneous injection is based on body weight.

Body weight less than 10 kg: Loading dose is 6 mg/kg once monthly for three doses. Maintenance dose is 3 mg/kg once monthly, beginning one month after the last loading dose.

Body weight of 10 kg to less than 20 kg: Loading dose is 6 mg/kg once monthly for three doses. Maintenance dose is 6 mg/kg once every three months quarterly, beginning one month after the last loading dose.

Body weight of 20 kg and above: Loading dose is 3 mg/kg once monthly for three doses. Maintenance dose is 3 mg/kg once every three months quarterly, beginning one month after the last loading dose.

J3490
J3590

Basic benefit and medical policy

Briumvi (ublituximab-xiiy)

Briumvi (ublituximab-xiiy) is considered established effective Dec. 28, 2022. 

Briumvi is a CD20-directed cytolytic antibody indicated for the treatment of relapsing forms of multiple sclerosis to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease in adults.

Dosage and administration:

  • Hepatitis B virus screening and quantitative serum immunoglobulin screening are required before first dose.
  • Pre-medicate with methylprednisolone (or an equivalent corticosteroid) and an antihistamine (e.g., diphenhydramine) prior to each infusion.
  • Administer Briumvi by intravenous infusion:
    • First infusion: 150 mg intravenous infusion
    • Second infusion: 450 mg intravenous infusion two weeks after the first infusion
    • Subsequent Infusions: 450 mg intravenous infusion 24 weeks after the first infusion and every 24 weeks thereafter
  • Must be diluted in 0.9% sodium chloride Injection, USP prior to administration.
  • Monitor patients closely during and for at least one hour after the completion of the first two infusions. Post-infusion monitoring of subsequent infusions is at physician discretion unless infusion reaction and/or hypersensitivity has been observed.

Dosage forms and strengths:

Injection: 150 mg/6 mL (25 mg/mL) in a single-dose vial

Coverage of Briumvi is provided when all the following are met:

  • Won’t be used in combination with other disease-modifying treatments of multiple sclerosis
  • Trial and failure, contraindication, or intolerance to the preferred drugs as listed in Blue Cross Blue Shield of Michigan’s utilization management medical drug list and/or Blue Cross’ prior authorization and step therapy documents

This drug isn’t a benefit for URMBT.

J3490
J3590

Basic benefit and medical policy

Iheezo (chloroprocaine hydrochloride)

Effective Sept. 27, 2022, Iheezo (chloroprocaine hydrochloride) is covered for the following FDA-approved indications:

  • Iheezo (chloroprocaine hydrochloride) is an ester anesthetic indicated for ocular surface anesthesia.

Dosage and administration:

The recommended dose of Iheezo (chloroprocaine hydrochloride) is three drops applied topically to the ocular surface in the area of the planned procedure.

Iheezo (chloroprocaine hydrochloride) may be reapplied as needed to maintain anesthetic effect.

Dosage forms and strengths:

Iheezo (chloroprocaine hydrochloride ophthalmic gel) 3% contains 24 mg of chloroprocaine hydrochloride per vial (800 mg). Clear, colorless to light yellow gel in single-patient-use vial.

Iheezo (chloroprocaine hydrochloride) isn’t a benefit for URMBT.

J3490
J3590

Basic benefit and medical policy

Sunlenca (lenacapavir)

Sunlenca (lenacapavir) is considered established, effective Dec. 22, 2022. 

Sunlenca, a human immunodeficiency virus type 1, or HIV-1, capsid inhibitor, in combination with other antiretrovirals, is indicated for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug resistant HIV-1 infection failing their current antiretroviral regimen due to resistance, intolerance or safety considerations.

Dosage and administration:

Recommended dosage: Initiation with one of two options followed by once every six-months maintenance dosing. Tablets may be taken without regard to food.

Initiation Option 1

Day 1: 927 mg by subcutaneous injection (2 x 1.5 mL injections) 600 mg orally (2 x 300 mg tablets)
Day 2: 600 mg orally (2 x 300 mg tablets)

Initiation Option 2

Day: 1 600 mg orally (2 x 300 mg tablets)
Day 2: 600 mg orally (2 x 300 mg tablets)
Day 8: 300 mg orally (1 x 300 mg tablet)
Day 15: 927 mg by subcutaneous injection (2 x 1.5 mL injections)

Maintenance

927 mg by subcutaneous injection (2 x 1.5 mL injections) every six months (26 weeks) from the date of the last injection +/-2 weeks.

  • Missed dose: If more than 28 weeks since last injection and clinically appropriate to continue Sunlenca, restart initiation from Day 1, using either Option 1 or Option 2.
  • Two 1.5 mL subcutaneous injections are required for complete dose.

Dosage forms and strengths:

Tablets: 300 mg Injection: 463.5 mg/1.5 mL (309 mg/mL) in single-dose vials

Coverage of Sunlenca is provided when all the following are met:

  • Will be used in combination with other anti-retroviral therapy for the treatment of human immunodeficiency virus type 1, or HIV-1.
  • Patient is heavily treatment-experienced with multidrug resistant HIV-1 infection based on the following:
    • Documented resistance to at least one antiretroviral medication from three different classes of drugs.
  • Patient is failing their current antiretroviral regimen.
  • Trial and failure, contraindication, or intolerance to the preferred drugs as listed in Blue Cross Blue Shield of Michigan’s utilization management medical drug list and/or Blue Cross’ prior authorization and step therapy documents.

This drug isn’t a benefit for URMBT.

J3490
J3590

Basic benefit and medical policy

Xenoview (xenon Xe 129 hyperpolarized)

Effective Dec. 23, 2022, Xenoview (xenon Xe 129 hyperpolarized) is covered for the following FDA-approved indications:

  • Xenoview, prepared from the Xenon Xe 129 Gas Blend, is a hyperpolarized contrast agent indicated for use with an MRI for evaluation of lung ventilation in adults and pediatric patients aged 12 and older.

Limitations of use:

Xenoview hasn’t been evaluated for use with lung perfusion imaging.

Dosage and administration:

  • The recommended target dose of Xenoview for adult and pediatric patients ages 12 and older is 75 mL to 100 mL dose equivalent, or DE, of hyperpolarized xenon Xe 129 by oral inhalation of the entire contents of one Xenoview Dose Delivery Bag. 
  • Each bag contains at least 75 mL DE of hyperpolarized xenon Xe 129 with a recommended target DE range of 75 mL to 100 mL measured within five minutes of administration, in a volume of 250 mL to 750 mL total xenon with additional nitrogen, NF (99.999% purity) added to reach a total volume of 1,000 mL.
  • Administer dose within five minutes of DE measurement.
  • Initiate imaging immediately after inhalation.

Dosage forms and strengths:

  • Xenoview is a clear, colorless, odorless gas contained in a 1,000 mL Xenoview Dose Delivery Bag. The bag contains at least 75 mL DE of hyperpolarized xenon Xe 129 in a volume of 250 mL to 750 mL total xenon.
  • The strength is DE per 1,000 mL administered. The minimum DE for a dose of Xenoview is 75 mL with a recommended DE target range of 75 to 100 mL. DE of greater than 100 mL is acceptable.

Xenoview (xenon Xe 129 hyperpolarized) isn’t a benefit for URMBT.

J9047

    

Basic benefit and medical policy

Kyprolis (carfilzomib)

Effective Aug. 1, 2022, Kyprolis (carfilzomib) is covered for the following FDA-approved indications:

  • Kyprolis (carfilzomib) is a proteasome inhibitor indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination with isatuximab and dexamethasone.

Dosage and administration:

Regimen: Kyprolis and dexamethasone (Kd) or Kyprolis, Daratumumab and Dexamethasone (DKd) or Kyprolis, Daratumumab and hyaluronidase-fihj and Dexamethasone (DKd) or Kyprolis, Isatuximab and Dexamethasone (Isa-Kd) or Kyprolis Monotherapy.

Dosage: 20/56 mg/m2 twice weekly 

Infusion time: 30 minutes

J9358

Basic benefit and medical policy

Enhertu (fam-trastuzumab deruxtecan-nxki)

Enhertu (fam-trastuzumab deruxtecan-nxki) is payable for the updated FDA indications, effective Nov. 4, 2022:

  • Adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer, as determined by an FDA-approved test, who have received a prior chemotherapy in the metastatic setting or developed disease recurrence during or within six months of completing adjuvant chemotherapy.

None of the information included in this billing chart is intended to be legal advice and, as such, it remains the provider’s responsibility to ensure that all coding and documentation are done in accordance with all applicable state and federal laws and regulations.

Professional

Behavioral health telehealth flexibilities for Medicare Advantage members to continue after PHE ends

During the COVID-19 public health emergency, the Centers for Medicare & Medicaid Services temporarily waived certain requirements and allowed flexibilities for providing telehealth services for behavioral health care. The Consolidated Appropriations Act, 2023, extended these flexibilities through Dec. 31, 2024. Some of these flexibilities will become permanent.

Blue Cross Blue Shield of Michigan and Blue Care Network will follow Medicare telehealth guidelines for our Medicare Plus Blue℠ and BCN Advantage℠  members.

Flexibilities becoming permanent for Medicare members:

  • Members will continue to have the same coverage for telehealth services for behavioral health care received in their homes.
  • Federally Qualified Health Centers and Rural Health Clinics can serve as distant site providers for behavioral health telehealth services.
  • The originating site for behavioral health telehealth services has no geographic restrictions.
  • Providers can deliver behavioral health telehealth services using audio-only communication platforms.
  • Rural hospital emergency departments are accepted as originating sites.

Temporary Medicare flexibilities that will end on Dec. 31, 2024:

  • The requirement for an in-person visit within six months of an initial behavioral health telehealth service, and annually thereafter, is waived until Dec. 31, 2024.

For more information on these changes, visit the Telehealth policy changes after the COVID-19 public health emergency** webpage on telehealth.hhs.gov.

**Blue Cross Blue Shield of Michigan and Blue Care Network don’t own or control this website.


MyMichigan Family Practice Center: Building a high-functioning team

This is the second article in a series highlighting some top performers in the Patient-Centered Medical Home Designation Program.

Dr. Sasha Savage

Dr. Sasha Savage

When Sasha Savage, M.D., attended a conference on the Patient-Centered Medical Home model, held in Savannah, Georgia, in 2008, he was intrigued and impressed. He networked with the presenters to gather additional information, then headed home to think about how he could begin implementing the PCMH model in his own practice.

“This represented a completely different perspective on care delivery,” said Dr. Savage, who practices at MyMichigan Family Practice Center in Midland, part of University of Michigan Health. “I recognized we had a huge opportunity to improve performance by implementing the PCMH model.”

PCMH uses a team-based approach to provide efficient, cost-effective care that’s centered around the patient. The goal is to help prevent disease, reduce hospitalizations and emergency department visits, track patient care and better manage common and chronic medical conditions to ensure patients are getting the right care at the right time in the right setting.

Becoming a PCMH practice

Dr. Savage’s first task after attending the conference was to reach out to his employed physician group, MyMichigan Medical Group, to get performance data. He and his colleagues analyzed the data to determine opportunities for improvement and establish initiatives. He then built a business model and worked with the health system executives and providers in the practice to get their buy-in to move forward. Educating providers and staff about PCMH was a key element of implementation, along with support from Blue Cross Blue Shield of Michigan.

Next, he set about building an effective care team. “At our practice, all team members have the innate ability to perform and participate in all practice initiatives,” said Dr. Savage. “All team members are considered equal and important to success in improving patient outcomes. All staff are engaged in discussions around improvement. The supervisory team’s role is to remove barriers that hold people back.” 

Today, in addition to physicians and other key staff members, the practice includes a behavioral health care manager, chronic care manager, pharmacist and a community health worker.

Building and maintaining a successful team

The practice also serves as a training facility for 24 resident physicians per year. Eight faculty attending physicians oversee and advise the residents. “Each faculty provider advises two to four residents,” explained Bonnie Khabir, the practice manager. “Faculty don’t use hospitalists. They make rounds on patients in the hospital to facilitate transitions of care.”

Khabir added that residents come to the clinic every day and are critiqued on patient engagement and clinical matters. They also participate in quality improvement projects as part of their training.

The practice sends out a Quality Corner email each month and maintains a Quality Book that contains the data and reports the staff uses to close gaps in care. Staff is encouraged to regularly review the book and to reach out to patients to ensure they receive timely services.

Dr. Savage stands with Meranda Collins, left, and Bonnie Khabir, right.

Dr. Savage stands
with Meranda Collins, left,
and Bonnie Khabir, right.

“A focus of residency training in this practice is how to develop a highly efficient and effective team,” said Khabir. “The practice has a scheduling coordinator who assists with transitioning patients as the resident rotates out of the practice to ensure smooth transition to a new provider.”

According to Meranda Collins, R.N. supervisor, ongoing education is another factor contributing to the success of the practice. “All staff are coached one-on-one as needed, with a focus on educational opportunities for everyone.”

This approach has led to the development of a high-functioning team. “We work to support our staff to prevent burnout and dissatisfaction,” Dr. Savage said. He added that the staff recently received training in improving the provider-patient relationships and how to cope with challenging behavior.

Following are some other processes that have been initiated to encourage team building:

  • Huddles, which are short, stand-up meetings (10 minutes or less) that typically take place at the start of the workday
  • Ongoing communications on tips and tactics for appropriate documentation and quality improvement
  • A culture that encourages providers and staff to suggest performance improvement ideas
  • Team-building events

Asked if he had any advice for other practices that want to build a high-functioning team that creates a good patient experience, Dr. Savage replied, “Build a culture of excellence, engage staff and ensure that all team members feel valued and important. If you want to go fast, go alone, but if you want to succeed, build a team.”


Pilot kidney health management program offered to URMBT Blue Cross non-Medicare members starting in May

Chronic kidney disease affects more than 1 in 7 U.S. adults, and the majority of people aren’t aware they have it, according to the National Institute of Diabetes and Digestive and Kidney Diseases. To address this challenge, Blue Cross Blue Shield of Michigan is working with Healthmap Solutions, an independent specialty population management company that offers a kidney health management solution.

This small-scale pilot program targets UAW Retiree Medical Benefits Trust non-Medicare members diagnosed with chronic kidney disease, or CKD, stages 3 through 5, unspecified CKD and end-stage renal disease. Outreach to physicians is underway. Select members will be encouraged to register, starting in May. There is no cost for them to participate.

Using member and provider-facing teams, this program will complement office-based primary and specialty care services with care navigation to educate members while incorporating kidney-related comorbidity management and addressing unmet social needs. Among the goals are to slow disease progression, prevent unnecessary admissions and readmissions, and ensure appropriate transitions of care.

Healthmap will work with members and health care providers to assist in coordinating the start of dialysis or developing a personal renal replacement therapy plan to avoid unplanned dialysis.

If you have any questions or need additional information, send an email to jmurray2@bcbsm.com.


Don’t forget to register for 2023 virtual provider symposium sessions

Action item

Register for one of the upcoming virtual provider symposium sessions below.

As you may have read previously in The Record, this year’s virtual provider symposiums run throughout May and June. Physicians, physician assistants, nurse practitioners, nurses and coders can receive continuing education credits for attending. You’re welcome to register for any session listed below.

Click here to log in to the provider training website to register for sessions.

If you don’t already have access, you can easily create an account. Click here to register. We recommend that you use the same email address you use to communicate with Blue Cross Blue Shield of Michigan when creating the account.

Once you’re logged in to the provider training site, open the event calendar to sign up for any of the following sessions.

Reach for the Stars-HEDIS®/Star Measure Overview: For physicians and office staff responsible for closing gaps in care related to quality adult measures

Session

Date

Time

Reach for the Stars —HEDIS®/Star Measure Overview

May 10

9 to 10:30 a.m.

Reach for the Stars —HEDIS®/Star Measure Overview

May 18

12 to 1:30 p.m.

Reach for the Stars -—HEDIS®/Star Measure Overview

May 23

2 to 3:30 p.m.

Reach for the Stars —HEDIS®/Star Measure Overview

June 1

8 to 9:30 a.m.

Reach for the Stars — HEDIS®/Star Measure Overview

June 6

12 to 1:30 p.m.

Patient Experience: For physicians and office staff responsible for creating positive patient experiences. Learn how to ensure your practice has the knowledge and tools needed to set and meet patients’ expectations.

Session

Date

Time

Patient Experience — Best Practices for the New Normal

May 2

9 to 10:30 a.m.

Patient Experience — Best Practices for the New Normal

May 9

11:30 a.m. to 1 p.m.

Patient Experience — Best Practices for the New Normal

May 17

12 to 1:30 p.m.

Patient Experience — Best Practices for the New Normal

May 22

2 to 3:30 p.m.

Patient Experience — Best Practices for the New Normal

June 8

9 to 10:30 a.m.

Coding Complex Cases: For physicians, coders, billers and administrative staff

Session

Date

Time

2023 CPT Coding Updates and Coding Complex Cases

May 4

9 to 10 a.m.

2023 CPT Coding Updates and Coding Complex Cases

May 11

12 to 1 p.m.

2023 CPT Coding Updates and Coding Complex Cases

May 16

2 to 3 p.m.

2023 CPT Coding Updates and Coding Complex Cases

June 7

9 to 10 a.m.

2023 CPT Coding Updates and Coding Complex Cases

June 20

12 to 1 p.m.

Questions?

Contact Ellen Kraft at ekraft@bcbsm.com if you have questions about the sessions. Contact the provider training team at ProviderTraining@bcbsm.com if you have questions about registration or using the provider training website.

HEDIS® is a registered trademark of the National Committee for Quality Assurance.

Accreditation Statement: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Minnesota Medical Association and Blue Cross Blue Shields of Michigan. The Minnesota Medical Association (MMA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CME Statement: The Minnesota Medical Association designates this internet this internet live activity for a maximum of 4 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


New on-demand training available

Action item

Visit our provider training site to find new resources on topics that are important to your role.

Provider Experience continues to offer training resources for health care providers and staff. Our on-demand courses can help you work more efficiently with Blue Cross Blue Shield of Michigan and Blue Care Network.

We recently added the following new learning opportunities:

  • CMS Star measures overview for 2023: This course is an overview of HEDIS® quality measures that are also Medicare Star Ratings measures. Updated for 2023, the course has a new section about the CAHPS® survey, tips for closing gaps, clarifications on quality measure requirements and assistance with coding and documentation.
  • HEDIS® measures scenarios for 2023: This course shows you how to close quality gaps using the HEDIS® tip sheets. You’ll learn the tips and tricks through a series of scenarios where you’ll help figure out why the office is seeing gaps in specific measures. The course has been updated for 2023.

These are both on-demand courses, so you can complete them at your own pace. To locate the courses, enter Star for the CMS Star measures course and HEDIS for the HEDIS measures course in the search box at the upper right corner of the training site.

Also, check out the dashboard on our provider training site, which can enhance the training experience for health care providers and staff. The site features announcements of new courses, including those with CME offerings.

If you don’t already have access to the training site, you can request it by completing the following steps:

  • Open the registration page.
  • Complete the registration. We recommend using the same email you use to communicate with Blue Cross for provider-related needs. This will become your login ID.
  • Follow the link to log in.

If you need assistance creating your login ID or navigating the site, contact ProviderTraining@bcbsm.com.

HEDIS®, which stands for Healthcare Effectiveness Data and Information Set, is a registered trademark of the National Committee for Quality Assurance.


Lunch and learn webinars for physicians and coders focus on risk adjustment, coding

We’re offering educational webinars that will provide updated information on documentation and coding of common challenging diagnoses. These live, lunchtime sessions will also include an opportunity to ask any questions that you may have. 

Here’s our current schedule and the tentative topics for the webinars. These 30-minute sessions start at noon Eastern time. Log in to the provider training website and register for the session that best works with your schedule.

Session Date

Topic

May 17

Coding neoplasms

June 21

Coding diabetes and hypertension

July 19

Coding heart disease and vascular

Aug. 16

Tips for proper medical record documentation and coding MEAT

Sept. 20

Coding tips for COPD and asthma

Oct. 18

ICD-10-CM updates and changes for 2024

Nov. 15

Coding chronic kidney disease and rheumatoid arthritis

Dec. 13

CPT coding scenarios; a look at the new CPT codes for 2024

If you haven’t already registered for the provider training website, follow these steps:

  1. Click here to register.
  2. Complete the registration. We recommend using the same email you use to communicate with Blue Cross Blue Shield of Michigan for other needs. This will become your login ID.

Locating a session

Click here if you are already registered for the provider training website. On the provider training website, look in the Event Calendar or use the search feature with the keyword lunch to quickly locate all 2023 sessions.

You can listen to the previously recorded sessions too. Check out the following:  

Previously recorded

Topic

April 26

HCC and risk adjustment coding scenarios

For more information
If you have any questions about the sessions, contact April Boyce at aboyce@bcbsm.com. If you have questions regarding session or website registration, email ProviderTraining@bcbsm.com.


Patient support can reduce complications when managing chronic conditions

When chronic conditions, such as diabetes, hypertension or cardiovascular disease, are managed, complications are reduced. And when complications are reduced, the need for urgent or emergency care services, hospitalizations and readmissions also are reduced.

For quick reference, here are the latest Michigan Quality Improvement Consortium guidelines for these conditions:

Patient education and compliance are key factors to managing a chronic condition. Here is information to share with your patients from the Centers for Disease Control and Prevention:

For more information on Federal Employee Program® Service Benefit Plan incentive programs and benefits, health care providers and members can visit fepblue.org or call Customer Service at 1-800-482-3600.

**Blue Cross Blue Shield of Michigan doesn’t own or control this website.


Requirements for some medical benefit drugs change for most members

Blue Cross Blue Shield of Michigan and Blue Care Network encourage proper use of high-cost medications billed under the medical benefit. As part of this effort, we maintain comprehensive lists of requirements for our members.

In January through March 2023, we added requirements for some medical benefit drugs.

For Blue Cross commercial and BCN commercial members: We added prior authorization requirements and site-of-care requirements as shown in the table below.

HCPCS code

Brand name

Generic name

Requirement

Prior authorization

Site of care

J3590**

Adstiladrin®

nadofaragene firadenovec-vncg

 

J3590**

Briumvi™

ublituximab-xiiy

 

J3590**

Fylnetra®

pegfilgrastim-pbbk

 

J3590**

Lamzede

velmanase alfa-tycv

 

J3590**

Leqembi™

lecanemab

 

J3590**

Rolvedon™

eflapegrastim-xnst

 

J3590**

Rebyota™

fecal microbiota, live-jslm

 

J3590**

Spevigo®

spesolimab-sbzo

 

J3590**

Stimufend®

pegfilgrastim-fpgk

 

J3590**

Syfovre™

pegcetacoplan

 

J3590**

Vegzelma®

bevacizumab-adcd

 

J3590**

Xenpozyme™

olipudase alfa

 

For Medicare Plus Blue℠ and BCN Advantage℠ members: We added prior authorization requirements as shown in the table below.

HCPCS code

Brand name

Generic name

For dates of service on or after

J3590**

Leqembi™

lecanemab-irmb

Jan. 13, 2023

J3590**

Rolvedon™

eflapegrastim-xnst

March 1, 2023

J3590**

Stimufend®

pegfilgrastim-fpgk

March 1, 2023

J3590**

Vegzelma®

bevacizumab-adcd

March 1, 2023

J3590**

Rebyota™

fecal microbiota, live-jslm

March 1, 2023

Drug lists

For additional details, see the following drug lists:

These lists are also available by following these steps:

  1. Go to ereferrals.bcbsm.com.
  2. Click on Blue Cross or BCN.
  3. Click on Medical Benefit Drugs.
  4. Scroll down and click on the Blue Cross and BCN utilization management medical drug list or the Medicare Plus Blue and BCN Advantage drug list link.

Additional information about these requirements

We communicated these changes previously through provider alerts, which contain additional details. You can view the provider alerts at ereferrals.bcbsm.com and on our Provider Resources site, which is accessible through our provider portal at availity.com.***

Additional information for Blue Cross commercial groups

For Blue Cross commercial groups, prior authorization requirements apply only to groups that participate in the standard commercial Medical Drug Prior Authorization Program for drugs administered under the medical benefit. To determine whether a group participates in the prior authorization program, see the Specialty Pharmacy Prior Authorization Master Opt-in/out Group List. To find this list:

  1. Go to ereferrals.bcbsm.com.
  2. Click on Blue Cross.
  3. Click on Medical Benefit Drugs.
  4. Scroll down and click on the Group opt in/opt out list link.

Note: Blue Cross and Blue Shield Federal Employee Program® members and non-Medicare United Auto Workers Retiree Medical Benefits Trust members don't participate in the standard prior authorization program.

Reminder

A prior authorization approval isn’t a guarantee of payment. Health care providers need to verify eligibility and benefits for members.

**May be assigned a unique code in the future.

***Blue Cross Blue Shield of Michigan and Blue Care Network don’t own or control this website.

Availity® is an independent company that contracts with Blue Cross Blue Shield of Michigan and Blue Care Network to offer provider portal services.


Briumvi to have site-of-care requirement for most commercial members starting July 1

For dates of service on or after July 1, 2023, we’re adding a site-of-care requirement for Blue Cross Blue Shield of Michigan and Blue Care Network group and individual commercial members for the following drug covered under the medical benefit:

  • Briumvi™ (ublituximab-xiiy), HCPCS code J3590

The NovoLogix® online tool will prompt you to select a site of care when you submit prior authorization requests for this drug. If the request meets clinical criteria for the drug and is for one of the following sites of care, it will be approved automatically:

  • Doctor’s or other health care provider’s office
  • Ambulatory infusion center
  • The member’s home (from a home infusion therapy provider)

Additional information or documentation may be required for requests to administer Briumvi in an outpatient hospital setting.

As a reminder, this drug already requires prior authorization; providers can submit prior authorization requests using NovoLogix. The new site-of-care requirement is in addition to the current prior authorization requirement.

Members who start courses of treatment with Briumvi before July 1, 2023, will be able to continue receiving the drug in their current location until their existing authorization expires. If those members then continue treatment under a new prior authorization, the site-of-care requirement outlined above will apply.

Some groups not subject to these requirements

For Blue Cross commercial groups, the prior authorization and site-of-care requirements apply only to groups that participate in the standard commercial Medical Drug Prior Authorization Program for drugs administered under the medical benefit. To determine whether a group participates in the prior authorization program, see the Specialty Pharmacy Prior Authorization Master Opt-in/out Group list.

Note: Blue Cross and Blue Shield Federal Employee Program® members and UAW Retiree Medical Benefits Trust (non-Medicare) members don’t participate in the standard prior authorization program.

List of requirements

For a full list of requirements related to drugs covered under the medical benefit, see the Blue Cross and BCN utilization management medical drug list for Blue Cross commercial and BCN commercial members. We’ll update this list prior to July 1, 2023.

You can access this list and other information about requesting prior authorization at ereferrals.bcbsm.com, at these locations:

As a reminder, authorization isn't a guarantee of payment. Health care practitioners need to verify eligibility and benefits for members.


Rolvedon to require prior authorization for URMBT members with Blue Cross non-Medicare plans

For dates of service on or after May 31, 2023, Rolvedon™ (eflapegrastim-xnst), HCPCS code J1449, will require prior authorization through Carelon Medical Benefits Management (formerly known as AIM Specialty Health®) for UAW Retiree Medical Benefits Trust members with Blue Cross Blue Shield of Michigan non-Medicare plans.

This drug is covered under the medical benefit.

The prior authorization requirement applies only when Rolvedon is administered in an outpatient setting.

Note: The prior authorization requirement doesn’t apply to the UAW Retiree Health Care Trust (group number 70605) or the UAW International Union (group number 71714).

How to submit authorization requests

Submit prior authorization requests to Carelon using one of the following methods:

  • Through the Carelon ProviderPortal, which you can access by doing one of the following:
    • Logging in to our provider portal (availity.com),** clicking on Payer Spaces and then clicking on the BCBSM and BCN logo. This takes you to the Blue Cross and BCN payer space where you’ll click on the Carelon ProviderPortal tile.
    • Logging in directly to the Carelon ProviderPortal at providerportal.com,**
  • By calling the Carelon Contact Center at 1-844-377-1278

More about authorization requirement

Authorization isn’t a guarantee of payment. As always, health care practitioners need to verify eligibility and benefits for members.

For additional information on requirements related to drugs covered under the medical benefit for URMBT members with Blue Cross non-Medicare plans, see:

We’ll update the pertinent drug lists to reflect the information in this message prior to the effective date.

**Blue Cross Blue Shield of Michigan and Blue Care Network don’t own or control this website.

Carelon Medical Benefits Management (formerly known as AIM Specialty Health) is an independent company that contracts with Blue Cross Blue Shield of Michigan and Blue Care Network to manage authorizations for select services.

Availity® is an independent company that contracts with Blue Cross Blue Shield of Michigan and Blue Care Network to offer provider portal services.


We made some questionnaire changes in e-referral system

On March 26 and April 9, 2023, we added, updated and removed questionnaires in the e-referral system. We also made changes in the corresponding preview questionnaires on the ereferrals.bcbsm.com website.

As a reminder, we use our authorization criteria, our medical policies and your answers to the questionnaires in the e-referral system when making utilization management determinations on your authorization requests.

New questionnaire

On March 26, we added a Breast reduction questionnaire that’s specific to BCN Advantage℠ members. This questionnaire will open for adolescent and adult BCN Advantage members for procedure code *19318.

Updated questionnaires

We updated the following questionnaires on the date specified below:


Questionnaire

Opens for

Updates

Release date

Breast reduction

BCN commercial

No longer opens for BCN Advantage members. This questionnaire continues to open for procedure code *19318 for BCN commercial members.
As noted above, a separate questionnaire opens for BCN Advantage members.

March 26

Dental general anesthesia or repair of trauma to natural teeth

  • BCN commercial
  • BCN Advantage

Updated the wording of a question.

April 9

Endovascular intervention, peripheral artery

  • Medicare Plus Blue℠
  • BCN commercial
  • BCN Advantage

Updated the wording of a question

March 26

Hammertoe correction surgery

  • Medicare Plus Blue
  • BCN commercial
  • BCN Advantage

Updated the wording of some questions

April 9

Prostatic urethral lift

  • BCN commercial
  • BCN Advantage
  • Updated the wording of a question
  • Removed a question

March 26

Radiofrequency ablation (RFA), cardiac atrial fibrillation or atrial flutter

  • Medicare Plus Blue
  • BCN commercial
  • BCN Advantage

Updated the wording of a question

April 9

Radiofrequency ablation (RFA), cardiac frequent monomorphic premature ventricular contractions

  • Medicare Plus Blue
  • BCN commercial
  • BCN Advantage

Updated the wording of some questions

April 9

Radiofrequency ablation (RFA), cardiac nonsustained ventricular tachycardia

  • Medicare Plus Blue
  • BCN commercial
  • BCN Advantage

Updated the wording of some questions

April 9

Radiofrequency ablation (RFA), cardiac suspected AVNRT, AVRT or focal atrial tachycardia

  • Medicare Plus Blue
  • BCN commercial
  • BCN Advantage

Updated the wording of some questions

April 9

Radiofrequency ablation (RFA), cardiac sustained (more than 30 seconds) ventricular tachycardia

  • Medicare Plus Blue
  • BCN commercial
  • BCN Advantage

Updated the wording of some questions

April 9

Radiofrequency ablation (RFA), cardiac treatment for preexcitation syndrome or WPW syndrome

  • Medicare Plus Blue
  • BCN commercial
  • BCN Advantage

Updated the wording of some questions

April 9

Responsive neurostimulator/deep brain stimulation trigger questionnaire

  • BCN commercial
  • BCN Advantage

No longer opens for procedure code *61868

March 26

Responsive neurostimulation for the treatment of refractory partial epilepsy

  • BCN commercial
  • BCN Advantage

No longer opens for procedure code *61868

March 26

Thyroidectomy, partial

  • Medicare Plus Blue
  • BCN commercial
  • BCN Advantage

Updated the wording of some questions

April 9

Thyroidectomy, total

  • Medicare Plus Blue
  • BCN commercial
  • BCN Advantage

Updated the wording of a question

April 9

Varicose vein treatment

  • BCN commercial
  • BCN Advantage
  • Opens for procedure code *37799
  • Updated the wording of some questions

March 26

Removed questionnaire

On March 26, we removed the Blepharoplasty, lower lid questionnaire. Although this service continues to require prior authorization for Medicare Plus Blue, BCN commercial and BCN Advantage members, the questionnaire no longer opens.

Preview questionnaires

Preview questionnaires show the questions you’ll need to answer so you can prepare your answers ahead of time. To access them, go to ereferrals.bcbsm.com and follow instructions below:

  • For BCN: Click on BCN and then click on Authorization Requirements & Criteria. Scroll down and look under the Authorization criteria and preview questionnaires heading.
  • For Medicare Plus Blue: Click on Blue Cross and then click on Authorization Requirements & Criteria. Scroll down and look under the Authorization criteria and preview questionnaires – Medicare Plus Blue heading.

Authorization criteria and medical policies

The pertinent authorization criteria and medical policies are also available on the Authorization Requirements & Criteria pages.


Reminder: Anatomical modifiers required

In the September 2021 Record, we let you know that we require anatomical modifiers for surgical procedure codes. Anatomical modifiers identify the specific area of the body where a procedure is performed. Requiring these modifiers aligns with AMA CPT guidelines and supports our commitment to implementing payment integrity solutions that enhance payment accuracy.

Please be sure to append the appropriate modifier to surgical procedures. Claims that are submitted without the appropriate anatomical modifier may receive a denial. 

Facility

Starting June 1, requests for commercial LTACH admissions and extensions must be submitted through e-referral

Long-term acute care hospitals, or LTACHs, in Michigan must submit prior authorization requests through the e-referral system and not by fax, starting June 1, 2023. This applies to requests for our Blue Cross Blue Shield of Michigan and Blue Care Network commercial members for:

  • Initial admissions
  • Additional days (extensions)

Many LTACH providers in Michigan currently use the Blue Cross and BCN LTACH Assessment Form to fax their prior authorization requests.

For Michigan providers

Starting June 1, 2023, we’ll accept faxes only for urgent requests and when the e-referral system isn’t available. Follow the instructions on the document titled e-referral system maintenance times and what to do.

If we receive a form for an admission or extension by fax when the e-referral system is available, we won’t accept it. We’ll notify you by fax or phone that you must submit the request through the e-referral system.

For non-Michigan providers

LTACH providers outside of Michigan can either:

  • Continue to submit requests by fax.
  • Submit requests through the e-referral system. For additional information and steps to access the e-referral system, refer to the non-Michigan providers section of the document titled Determining prior authorization requirements for members. Prior authorization is required for LTACH stays.

Training opportunities

We’ll schedule webinars in May on how to use the e‑referral system. Watch for upcoming communications.

Sign up now to use e-referral system

Get information on our ereferrals.bcbsm.com website as follows:

How to access the e-referral system

Access the e-referral system through our provider portal:

  • Log in to availity.com.**
  • Click on Payer Spaces on the menu bar and then click on the BCBSM and BCN logo.
  • On the Applications tab, scroll down and click on the e-referral tile.

You’ll first need to register for access to our portal if you haven’t already done that. Refer to the Register for web tools webpage for instructions on how to:

  • Register for access to Availity.
  • Set up the e-referral tool within Availity.

Submit Medicare Advantage requests to naviHealth

naviHealth manages prior authorization requests for post-acute care admissions for our Medicare Plus Blue℠ and BCN Advantage℠ members.

**Blue Cross Blue Shield of Michigan and Blue Care Network don’t own or control this website.

Availity is an independent company that contracts with Blue Cross Blue Shield of Michigan and Blue Care Network to offer provider portal services.

naviHealth is an independent company that manages authorizations for post-acute care services for Blue Cross Blue Shield of Michigan and Blue Care Network members who have Medicare Advantage plans.


COVID-19 DRG enhancements end with public health emergency

The federal Coronavirus Aid, Relief and Economic Security, or CARES, Act implemented a temporary inpatient diagnosis-related group enhancement for Original Medicare payments. The DRG enhancement represented a 20% increase in the weighting factor for inpatient DRG payments for Medicare patients diagnosed with COVID-19.

Blue Cross Blue Shield of Michigan and Blue Care Network applied the DRG enhancement to our Medicare Advantage plans (Medicare Plus Blue℠ and BCN Advantage℠) for both in-network and out-of-network providers.

When the public health emergency ends on May 11, 2023, the DRG enhancement will also end.

For more information on changes occurring with the end of the public health emergency, see our Temporary changes due to the COVID-19 pandemic document.


Lunch and learn webinars for physicians and coders focus on risk adjustment, coding

We’re offering educational webinars that will provide updated information on documentation and coding of common challenging diagnoses. These live, lunchtime sessions will also include an opportunity to ask any questions that you may have. 

Here’s our current schedule and the tentative topics for the webinars. These 30-minute sessions start at noon Eastern time. Log in to the provider training website and register for the session that best works with your schedule.

Session Date

Topic

May 17

Coding neoplasms

June 21

Coding diabetes and hypertension

July 19

Coding heart disease and vascular

Aug. 16

Tips for proper medical record documentation and coding MEAT

Sept. 20

Coding tips for COPD and asthma

Oct. 18

ICD-10-CM updates and changes for 2024

Nov. 15

Coding chronic kidney disease and rheumatoid arthritis

Dec. 13

CPT coding scenarios; a look at the new CPT codes for 2024

If you haven’t already registered for the provider training website, follow these steps:

  1. Click here to register.
  2. Complete the registration. We recommend using the same email you use to communicate with Blue Cross Blue Shield of Michigan for other needs. This will become your login ID.

Locating a session

Click here if you are already registered for the provider training website. On the provider training website, look in the Event Calendar or use the search feature with the keyword lunch to quickly locate all 2023 sessions.

You can listen to the previously recorded sessions too. Check out the following:  

Previously recorded

Topic

April 26

HCC and risk adjustment coding scenarios

For more information
If you have any questions about the sessions, contact April Boyce at aboyce@bcbsm.com. If you have questions regarding session or website registration, email ProviderTraining@bcbsm.com.


Reminder: Outpatient services provided during inpatient admission should be reported with inpatient claim

Blue Cross Blue Shield of Michigan continues to expand its claim editing process to further support payment policy.  

Beginning in May 2023, Blue Cross payment policy requires that outpatient services provided during an inpatient admission be reported with the inpatient claim if there is a similar diagnosis.

Claims submitted for outpatient services during an inpatient admission may be denied if they’re billed separately.


Requirements for some medical benefit drugs change for most members

Blue Cross Blue Shield of Michigan and Blue Care Network encourage proper use of high-cost medications billed under the medical benefit. As part of this effort, we maintain comprehensive lists of requirements for our members.

In January through March 2023, we added requirements for some medical benefit drugs.

For Blue Cross commercial and BCN commercial members: We added prior authorization requirements and site-of-care requirements as shown in the table below.

HCPCS code

Brand name

Generic name

Requirement

Prior authorization

Site of care

J3590**

Adstiladrin®

nadofaragene firadenovec-vncg

 

J3590**

Briumvi™

ublituximab-xiiy

 

J3590**

Fylnetra®

pegfilgrastim-pbbk

 

J3590**

Lamzede

velmanase alfa-tycv

 

J3590**

Leqembi™

lecanemab

 

J3590**

Rolvedon™

eflapegrastim-xnst

 

J3590**

Rebyota™

fecal microbiota, live-jslm

 

J3590**

Spevigo®

spesolimab-sbzo

 

J3590**

Stimufend®

pegfilgrastim-fpgk

 

J3590**

Syfovre™

pegcetacoplan

 

J3590**

Vegzelma®

bevacizumab-adcd

 

J3590**

Xenpozyme™

olipudase alfa

 

For Medicare Plus Blue℠ and BCN Advantage℠ members: We added prior authorization requirements as shown in the table below.

HCPCS code

Brand name

Generic name

For dates of service on or after

J3590**

Leqembi™

lecanemab-irmb

Jan. 13, 2023

J3590**

Rolvedon™

eflapegrastim-xnst

March 1, 2023

J3590**

Stimufend®

pegfilgrastim-fpgk

March 1, 2023

J3590**

Vegzelma®

bevacizumab-adcd

March 1, 2023

J3590**

Rebyota™

fecal microbiota, live-jslm

March 1, 2023

Drug lists

For additional details, see the following drug lists:

These lists are also available by following these steps:

  1. Go to ereferrals.bcbsm.com.
  2. Click on Blue Cross or BCN.
  3. Click on Medical Benefit Drugs.
  4. Scroll down and click on the Blue Cross and BCN utilization management medical drug list or the Medicare Plus Blue and BCN Advantage drug list link.

Additional information about these requirements

We communicated these changes previously through provider alerts, which contain additional details. You can view the provider alerts at ereferrals.bcbsm.com and on our Provider Resources site, which is accessible through our provider portal at availity.com.***

Additional information for Blue Cross commercial groups

For Blue Cross commercial groups, prior authorization requirements apply only to groups that participate in the standard commercial Medical Drug Prior Authorization Program for drugs administered under the medical benefit. To determine whether a group participates in the prior authorization program, see the Specialty Pharmacy Prior Authorization Master Opt-in/out Group List. To find this list:

  1. Go to ereferrals.bcbsm.com.
  2. Click on Blue Cross.
  3. Click on Medical Benefit Drugs.
  4. Scroll down and click on the Group opt in/opt out list link.

Note: Blue Cross and Blue Shield Federal Employee Program® members and non-Medicare United Auto Workers Retiree Medical Benefits Trust members don't participate in the standard prior authorization program.

Reminder

A prior authorization approval isn’t a guarantee of payment. Health care providers need to verify eligibility and benefits for members.

**May be assigned a unique code in the future.

***Blue Cross Blue Shield of Michigan and Blue Care Network don’t own or control this website.

Availity® is an independent company that contracts with Blue Cross Blue Shield of Michigan and Blue Care Network to offer provider portal services.


Briumvi to have site-of-care requirement for most commercial members starting July 1

For dates of service on or after July 1, 2023, we’re adding a site-of-care requirement for Blue Cross Blue Shield of Michigan and Blue Care Network group and individual commercial members for the following drug covered under the medical benefit:

  • Briumvi™ (ublituximab-xiiy), HCPCS code J3590

The NovoLogix® online tool will prompt you to select a site of care when you submit prior authorization requests for this drug. If the request meets clinical criteria for the drug and is for one of the following sites of care, it will be approved automatically:

  • Doctor’s or other health care provider’s office
  • Ambulatory infusion center
  • The member’s home (from a home infusion therapy provider)

Additional information or documentation may be required for requests to administer Briumvi in an outpatient hospital setting.

As a reminder, this drug already requires prior authorization; providers can submit prior authorization requests using NovoLogix. The new site-of-care requirement is in addition to the current prior authorization requirement.

Members who start courses of treatment with Briumvi before July 1, 2023, will be able to continue receiving the drug in their current location until their existing authorization expires. If those members then continue treatment under a new prior authorization, the site-of-care requirement outlined above will apply.

Some groups not subject to these requirements

For Blue Cross commercial groups, the prior authorization and site-of-care requirements apply only to groups that participate in the standard commercial Medical Drug Prior Authorization Program for drugs administered under the medical benefit. To determine whether a group participates in the prior authorization program, see the Specialty Pharmacy Prior Authorization Master Opt-in/out Group list.

Note: Blue Cross and Blue Shield Federal Employee Program® members and UAW Retiree Medical Benefits Trust (non-Medicare) members don’t participate in the standard prior authorization program.

List of requirements

For a full list of requirements related to drugs covered under the medical benefit, see the Blue Cross and BCN utilization management medical drug list for Blue Cross commercial and BCN commercial members. We’ll update this list prior to July 1, 2023.

You can access this list and other information about requesting prior authorization at ereferrals.bcbsm.com, at these locations:

As a reminder, authorization isn't a guarantee of payment. Health care practitioners need to verify eligibility and benefits for members.


Rolvedon to require prior authorization for URMBT members with Blue Cross non-Medicare plans

For dates of service on or after May 31, 2023, Rolvedon™ (eflapegrastim-xnst), HCPCS code J1449, will require prior authorization through Carelon Medical Benefits Management (formerly known as AIM Specialty Health®) for UAW Retiree Medical Benefits Trust members with Blue Cross Blue Shield of Michigan non-Medicare plans.

This drug is covered under the medical benefit.

The prior authorization requirement applies only when Rolvedon is administered in an outpatient setting.

Note: The prior authorization requirement doesn’t apply to the UAW Retiree Health Care Trust (group number 70605) or the UAW International Union (group number 71714).

How to submit authorization requests

Submit prior authorization requests to Carelon using one of the following methods:

  • Through the Carelon ProviderPortal, which you can access by doing one of the following:
    • Logging in to our provider portal (availity.com),** clicking on Payer Spaces and then clicking on the BCBSM and BCN logo. This takes you to the Blue Cross and BCN payer space where you’ll click on the Carelon ProviderPortal tile.
    • Logging in directly to the Carelon ProviderPortal at providerportal.com,**
  • By calling the Carelon Contact Center at 1-844-377-1278

More about authorization requirement

Authorization isn’t a guarantee of payment. As always, health care practitioners need to verify eligibility and benefits for members.

For additional information on requirements related to drugs covered under the medical benefit for URMBT members with Blue Cross non-Medicare plans, see:

We’ll update the pertinent drug lists to reflect the information in this message prior to the effective date.

**Blue Cross Blue Shield of Michigan and Blue Care Network don’t own or control this website.

Carelon Medical Benefits Management (formerly known as AIM Specialty Health) is an independent company that contracts with Blue Cross Blue Shield of Michigan and Blue Care Network to manage authorizations for select services.

Availity® is an independent company that contracts with Blue Cross Blue Shield of Michigan and Blue Care Network to offer provider portal services.

No portion of this publication may be copied without the express written permission of Blue Cross Blue Shield of Michigan, except that BCBSM participating health care providers may make copies for their personal use. In no event may any portion of this publication be copied or reprinted and used for commercial purposes by any party other than BCBSM.

*CPT codes, descriptions and two-digit numeric modifiers only are copyright 2022 American Medical Association. All rights reserved.